Access cutting-edge non-hodgkin's lymphoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access non-hodgkin's lymphoma specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related non-hodgkin's lymphoma treatment provided free
This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. This entry-into-human (EIH) study is divided in 3 parts: dose escalation (Parts I and II) and dose expansion (Part III). Single-partic
Sponsor: Hoffmann-La Roche
Check if you qualify for this non-hodgkin's lymphoma clinical trial in New York, NY
If you're searching for non-hodgkin's lymphoma treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced non-hodgkin's lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.